Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels.
OBJECTIVE
The effect of pravastatin was evaluated using patient data accumulated in the data base of a hospital information system (HIS).


METHODS
We selected 130 patients treated with pravastatin 10 mg per day, for a minimum period of 4 weeks.


RESULTS
In the t test analysis, the reduction rates of total cholesterol (TC) and low-density lipoprotein (LDL) levels for pravastatin administration were 18%, and 27%, respectively. These values were similar to previous reports. The high-density lipoprotein (HDL) level, however, did not change significantly, although previous reports have shown an elevation of HDL levels. In an attempt to explain the origin of this difference, we studied the pretreatment value dependence of the cholesterol change using regression analysis. We found that pravastatin raised the HDL level in those cases where pretreatment values were lower than 58 mg.dl-1 and reduced it for higher values. We also showed that the reductions of TC, LDL and triglyceride (TG) levels correlated positively with their pretreatment values.
Narita
Y
Y
Center of Medical Information Science, Kochi Medical School, Japan.
Kitazoe
Y
Y
Kurihara
Y
Y
Okuhara
Y
Y
Takamatsu
K
K
Saito
N
N
Doi
Y
Y
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin